This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Princeton University. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Mark Esposito: Innovator in Cancer Treatment
Introduction
Mark Esposito is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds.
Latest Patents
Mark Esposito holds a patent for "Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers." This patent discloses compounds that inhibit aldehyde dehydrogenase isoform Ia3 (ALDHIa3) and are useful for treating various forms of cancer, particularly those that are metastatic or resistant to chemotherapy. The compounds are designed to provide new therapeutic options for patients facing challenging cancer diagnoses.
Career Highlights
Esposito's work is primarily associated with Princeton University, where he has been involved in groundbreaking research. His focus on developing effective treatments for cancer has positioned him as a key figure in the scientific community.
Collaborations
One of his notable collaborators is Yibin Kang, with whom he has worked on various research projects aimed at advancing cancer treatment methodologies.
Conclusion
Mark Esposito's contributions to cancer research and treatment exemplify the impact of innovative thinking in the medical field. His patent for tetrahydroquinolino derivatives represents a significant step forward in the fight against metastatic and chemoresistant cancers.